Channa E. Schmeink, MD, Leon F. Massuger, MD, PhD, Charlotte H. Lenselink, MD, PhD, Wim G. Quint, PhD, Willem J. Melchers, PhD, and Ruud L. Bekkers, MD, PhD
OBJECTIVE: To estimate the effect of the menstrual cycle
and oral contraceptive pill (OCP) use on the prevalence,
incidence, and persistence of human papillomavirus
CONCLUSION: High-risk HPV detection was significantly
influenced by sample timing in the menstrual cycle when analyzed separately for OCP users and women with a natural menstrual cycle. This may have implications in the future, when high-risk HPV detection may
become a primary screening tool in cervical cancer prevention.
(Obstet Gynecol 2010;116:67–75)
My colleague Cynthia Janak and I presented research and date to the FDA about the potential dangers of the HPV vaccine due to the menstrual cycle in March of this year. This study backs up our concerns…and our research. In our humble opinion we have proven why this vaccine is dangerous to this age group of women.